Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 161

1.

Oral vaccination with Lactococcus lactis expressing the Vibrio cholerae Wzm protein to enhance mucosal and systemic immunity.

Zamri HF, Shamsudin MN, Rahim RA, Neela V.

Vaccine. 2012 May 2;30(21):3231-8. doi: 10.1016/j.vaccine.2012.02.012. Epub 2012 Mar 16.

PMID:
22426330
[PubMed - indexed for MEDLINE]
2.

Intranasal immunization with recombinant toxin-coregulated pilus and cholera toxin B subunit protects rabbits against Vibrio cholerae O1 challenge.

Kundu J, Mazumder R, Srivastava R, Srivastava BS.

FEMS Immunol Med Microbiol. 2009 Jul;56(2):179-84. doi: 10.1111/j.1574-695X.2009.00563.x. Epub 2009 May 5.

PMID:
19453752
[PubMed - indexed for MEDLINE]
3.

Transcutaneous immunization with a Vibrio cholerae O1 Ogawa synthetic hexasaccharide conjugate following oral whole-cell cholera vaccination boosts vibriocidal responses and induces protective immunity in mice.

Tarique AA, Kalsy A, Arifuzzaman M, Rollins SM, Charles RC, Leung DT, Harris JB, Larocque RC, Sheikh A, Bhuiyan MS, Saksena R, Clements JD, Calderwood SB, Qadri F, Kovác P, Ryan ET.

Clin Vaccine Immunol. 2012 Apr;19(4):594-602. doi: 10.1128/CVI.05689-11. Epub 2012 Feb 22.

PMID:
22357651
[PubMed - indexed for MEDLINE]
Free PMC Article
4.

Construction of novel vaccine strains of Vibrio cholerae co-expressing the Inaba and Ogawa serotype antigens.

Lebens M, Karlsson SL, Källgård S, Blomquist M, Ekman A, Nygren E, Holmgren J.

Vaccine. 2011 Oct 6;29(43):7505-13. doi: 10.1016/j.vaccine.2011.06.121. Epub 2011 Jul 30.

PMID:
21807059
[PubMed - indexed for MEDLINE]
5.

Oral administration of Lactococcus lactis expressing Helicobacter pylori Cag7-ct383 protein induces systemic anti-Cag7 immune response in mice.

Kim SJ, Lee JY, Jun DY, Song JY, Lee WK, Cho MJ, Kim YH.

FEMS Immunol Med Microbiol. 2009 Dec;57(3):257-68. doi: 10.1111/j.1574-695X.2009.00605.x. Epub 2009 Sep 1.

PMID:
19807786
[PubMed - indexed for MEDLINE]
6.

Robust gut associated vaccine-specific antibody-secreting cell responses are detected at the mucosal surface of Bangladeshi subjects after immunization with an oral killed bivalent V. cholerae O1/O139 whole cell cholera vaccine: comparison with other mucosal and systemic responses.

Shamsuzzaman S, Ahmed T, Mannoor K, Begum YA, Bardhan PK, Sack RB, Sack DA, Svennerholm AM, Holmgren J, Qadri F.

Vaccine. 2009 Feb 25;27(9):1386-92. doi: 10.1016/j.vaccine.2008.12.041. Epub 2009 Jan 13.

PMID:
19146897
[PubMed - indexed for MEDLINE]
7.

Construction and evaluation of a safe, live, oral Vibrio cholerae vaccine candidate, IEM108.

Liang W, Wang S, Yu F, Zhang L, Qi G, Liu Y, Gao S, Kan B.

Infect Immun. 2003 Oct;71(10):5498-504.

PMID:
14500467
[PubMed - indexed for MEDLINE]
Free PMC Article
8.

Transcutaneous immunization with a synthetic hexasaccharide-protein conjugate induces anti-Vibrio cholerae lipopolysaccharide responses in mice.

Rollenhagen JE, Kalsy A, Saksena R, Sheikh A, Alam MM, Qadri F, Calderwood SB, Kovác P, Ryan ET.

Vaccine. 2009 Aug 6;27(36):4917-22. doi: 10.1016/j.vaccine.2009.06.040. Epub 2009 Jun 27.

PMID:
19563890
[PubMed - indexed for MEDLINE]
Free PMC Article
9.

Lack of cross-protection against diarrhea due to Vibrio cholerae O139 (Bengal strain) after oral immunization of rabbits with V. cholerae O1 vaccine strain CVD103-HgR.

Albert MJ, Alam K, Ansaruzzaman M, Qadri F, Sack RB.

J Infect Dis. 1994 Jan;169(1):230-1. No abstract available.

PMID:
8277193
[PubMed - indexed for MEDLINE]
10.

Oral immunization with recombinant Lactococcus lactis confers protection against respiratory pneumococcal infection.

Villena J, Medina M, Raya R, Alvarez S.

Can J Microbiol. 2008 Oct;54(10):845-53. doi: 10.1139/w08-077.

PMID:
18923553
[PubMed - indexed for MEDLINE]
11.

The protective effect of recombinant Lactococcus lactis oral vaccine on a Clostridium difficile-infected animal model.

Yang XQ, Zhao YG, Chen XQ, Jiang B, Sun DY.

BMC Gastroenterol. 2013 Jul 17;13:117. doi: 10.1186/1471-230X-13-117.

PMID:
23865596
[PubMed - indexed for MEDLINE]
Free PMC Article
12.

Infection and immunity to Vibrio cholerae, Salmonella typhimurium and Escherichia coli in a rabbit model.

Guinée PA, Jansen WH, Rijpkema SG.

Zentralbl Bakteriol Mikrobiol Hyg A. 1988 Nov;270(1-2):260-9.

PMID:
2464884
[PubMed - indexed for MEDLINE]
13.

The vaccine candidate Vibrio cholerae 638 is protective against cholera in healthy volunteers.

García L, Jidy MD, García H, Rodríguez BL, Fernández R, Año G, Cedré B, Valmaseda T, Suzarte E, Ramírez M, Pino Y, Campos J, Menéndez J, Valera R, González D, González I, Pérez O, Serrano T, Lastre M, Miralles F, Del Campo J, Maestre JL, Pérez JL, Talavera A, Pérez A, Marrero K, Ledón T, Fando R.

Infect Immun. 2005 May;73(5):3018-24.

PMID:
15845509
[PubMed - indexed for MEDLINE]
Free PMC Article
14.

A proteoliposome based formulation administered by the nasal route produces vibriocidal antibodies against El Tor Ogawa Vibrio cholerae O1 in BALB/c mice.

Pérez JL, Acevedo R, Callicó A, Fernández Y, Cedré B, Año G, González L, Falero G, Talavera A, Pérez O, García L.

Vaccine. 2009 Jan 7;27(2):205-12. doi: 10.1016/j.vaccine.2008.10.052. Epub 2008 Nov 7.

PMID:
18996426
[PubMed - indexed for MEDLINE]
15.

Expression of hepatitis B virus surface antigen determinants in Lactococcus lactis for oral vaccination.

Zhang Q, Zhong J, Huan L.

Microbiol Res. 2011 Feb 20;166(2):111-20. doi: 10.1016/j.micres.2010.02.002. Epub 2010 Mar 12.

PMID:
20227266
[PubMed - indexed for MEDLINE]
Free Article
16.

Comparison of immune responses to the O-specific polysaccharide and lipopolysaccharide of Vibrio cholerae O1 in Bangladeshi adult patients with cholera.

Johnson RA, Uddin T, Aktar A, Mohasin M, Alam MM, Chowdhury F, Harris JB, LaRocque RC, Bufano MK, Yu Y, Wu-Freeman Y, Leung DT, Sarracino D, Krastins B, Charles RC, Xu P, Kovác P, Calderwood SB, Qadri F, Ryan ET.

Clin Vaccine Immunol. 2012 Nov;19(11):1712-21. doi: 10.1128/CVI.00321-12. Epub 2012 Sep 19.

PMID:
22993410
[PubMed - indexed for MEDLINE]
Free PMC Article
17.

Immunogenicity and protective efficacy of Vibrio cholerae outer membrane vesicles in rabbit model.

Roy N, Barman S, Ghosh A, Pal A, Chakraborty K, Das SS, Saha DR, Yamasaki S, Koley H.

FEMS Immunol Med Microbiol. 2010 Oct;60(1):18-27. doi: 10.1111/j.1574-695X.2010.00692.x.

PMID:
20528929
[PubMed - indexed for MEDLINE]
18.

Heterologous antigen expression in Vibrio cholerae vector strains.

Butterton JR, Beattie DT, Gardel CL, Carroll PA, Hyman T, Killeen KP, Mekalanos JJ, Calderwood SB.

Infect Immun. 1995 Jul;63(7):2689-96.

PMID:
7790086
[PubMed - indexed for MEDLINE]
Free PMC Article
19.

Peru-15, an improved live attenuated oral vaccine candidate for Vibrio cholerae O1.

Kenner JR, Coster TS, Taylor DN, Trofa AF, Barrera-Oro M, Hyman T, Adams JM, Beattie DT, Killeen KP, Spriggs DR, et al.

J Infect Dis. 1995 Oct;172(4):1126-9.

PMID:
7561195
[PubMed - indexed for MEDLINE]
20.

Oral vaccination of mice against Helicobacter pylori with recombinant Lactococcus lactis expressing urease subunit B.

Gu Q, Song D, Zhu M.

FEMS Immunol Med Microbiol. 2009 Aug;56(3):197-203. doi: 10.1111/j.1574-695X.2009.00566.x. Epub 2009 May 15.

PMID:
19453750
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk